Interaction of drugs with gut microbiota modulators

References

• Abraham BP, Quigley EMM. 2017. Probiotics in inflammatory bowel disease. Gastroenterol Clin North Am. 46(4):769–782.
   PubMed Web of Science ®Google Scholar
• Abuhelwa AY, Williams DB, Upton RN, Foster DJ. 2017. Food, gastrointestinal pH, and models of oral drug absorption. Eur J Pharm Biopharm. 112:234–248.
   PubMed Web of Science ®Google Scholar
• Ahnfelt-Rønne I, Nielsen OH, Bukhave K, Elmgreen J. 1987. Sulfasalazine and its anti-inflammatory metabolite, 5-aminosalicylic acid: effect on arachidonic acid metabolism in human neutrophils, and free radical scavenging. Adv Prostaglandin Thromboxane Leukot Res. 17b:918–922.
   PubMedGoogle Scholar
• Al-Salami H, Butt G, Fawcett JP, Tucker IG, Golocorbin-Kon S, Mikov M. 2008. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet. 33(2):101–106.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, Golocorbin-Kon S, Mikov M. 2012. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 37(2):99–108.
   PubMed Web of Science ®Google Scholar
• Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. 2017. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 14(6):356–365.
   PubMed Web of Science ®Google Scholar
• Alimirah M, Sadiq O, Gordon SC. 2020. Novel therapies in hepatic encephalopathy. Clin Liver Dis. 24(2):303–315.
   PubMed Web of Science ®Google Scholar
• Almazroo OA, Miah MK, Venkataramanan R. 2017. Drug metabolism in the liver. Clin Liver Dis. 21(1):1–20.
   PubMed Web of Science ®Google Scholar
• Angelucci F, Cechova K, Amlerova J, Hort J. 2019. Antibiotics, gut microbiota, and Alzheimer’s disease. J Neuroinflammation. 16(1):108.
   PubMed Web of Science ®Google Scholar
• Ashmawy SM, El-Gizawy SA, El Maghraby GM, Osman MA. 2019. Regional difference in intestinal drug absorption as a measure for the potential effect of P-glycoprotein efflux transporters. J Pharm Pharmacol. 71(3):362–370.
   PubMed Web of Science ®Google Scholar
• Asnicar F, Leeming ER, Dimidi E, Mazidi M, Franks PW, Al Khatib H, Valdes AM, Davies R, Bakker E, Francis L, et al. 2021. Blue poo: impact of gut transit time on the gut microbiome using a novel marker. Gut. 70(9):1665–1674.
   PubMed Web of Science ®Google Scholar
• Asok Kumar K, Mazumdar K, Dutta NK, Karak P, Dastidar SG, Ray R. 2004. Evaluation of synergism between the aminoglycoside antibiotic streptomycin and the cardiovascular agent amlodipine. Biol Pharm Bull. 27(7):1116–1120.
   PubMed Web of Science ®Google Scholar
• Athari Nik Azm S, Djazayeri A, Safa M, Azami K, Ahmadvand B, Sabbaghziarani F, Sharifzadeh M, Vafa M. 2018. Lactobacilli and bifidobacteria ameliorate memory and learning deficits and oxidative stress in β-amyloid (1–42) injected rats. Appl Physiol Nutr Metab. 43(7):718–726.
   PubMed Web of Science ®Google Scholar
• Atli O, Demir-Ozkay U, Ilgin S, Aydin TH, Akbulut EN, Sener E. 2016. Evidence for neurotoxicity associated with amoxicillin in juvenile rats. Hum Exp Toxicol. 35(8):866–876.
   PubMed Web of Science ®Google Scholar
• Azadkhan AK, Truelove SC, Aronson JK. 1982. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol. 13(4):523–528.
   PubMed Web of Science ®Google Scholar
• Barko PC, McMichael MA, Swanson KS, Williams DA. 2018. The gastrointestinal microbiome: a review. J Vet Intern Med. 32(1):9–25.
   PubMed Web of Science ®Google Scholar
• Basag SH, Dunlop JR, Searle AJ, Willson RL. 1978. Metronidazole (flagyl) and misonidazole (Ro-07-0582): reduction by facultative anaerobes and cytotoxic action on hypoxic bacteria and mammalian cells in vivo. Br J Cancer Suppl. 3:132–135.
   PubMedGoogle Scholar
• Basit AW, Lacey LF. 2001. Colonic metabolism of ranitidine: implications for its delivery and absorption. Int J Pharm. 227(1–2):157–165.
   PubMedGoogle Scholar
• Basit AW, Newton JM, Lacey LF. 2002. Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. Int J Pharm. 237(1–2):23–33.
   PubMed Web of Science ®Google Scholar
• Basit AW, Podczeck F, Newton JM, Waddington WA, Ell PJ, Lacey LF. 2004. The use of formulation technology to assess regional gastrointestinal drug absorption in humans. Eur J Pharm Sci. 21(2–3):179–189.
   PubMed Web of Science ®Google Scholar
• Beckers M, Bloem BR, Verbeek MM. 2022. Mechanisms of peripheral levodopa resistance in Parkinson’s disease. NPJ Parkinsons Dis. 8(1):56.
   PubMed Web of Science ®Google Scholar
• Benet LZ, Bowman CM, Koleske ML, Rinaldi CL, Sodhi JK. 2019. Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs. J Pharmacokinet Pharmacodyn. 46(2):155–163.
   PubMed Web of Science ®Google Scholar
• Bibbò S, Ianiro G, Giorgio V, Scaldaferri F, Masucci L, Gasbarrini A, Cammarota G. 2016. The role of diet on gut microbiota composition. Eur Rev Med Pharmacol Sci. 20(22):4742–4749.
   PubMed Web of Science ®Google Scholar
• Bojović K, Ignjatović ÐI, Soković Bajić S, Vojnović Milutinović D, Tomić M, Golić N, Tolinački M. 2020. Gut Microbiota dysbiosis associated with altered production of short chain fatty acids in children with neurodevelopmental disorders. Front Cell Infect Microbiol. 10:223.
   PubMed Web of Science ®Google Scholar
• Brown EG, Goldman SM. 2020. Modulation of the microbiome in Parkinson’s disease: diet, drug, stool transplant, and beyond. Neurotherapeutics. 17(4):1406–1417.
   PubMed Web of Science ®Google Scholar
• Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. 1983. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 28(7):609–615.
   PubMed Web of Science ®Google Scholar
• Chen HQ, Gong JY, Xing K, Liu MZ, Ren H, Luo JQ. 2021. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in antihypertensive treatment. Front Med. 8:742394.
   Web of Science ®Google Scholar
• Chilton CH, Pickering DS, Freeman J. 2018. Microbiologic factors affecting Clostridium difficile recurrence. Clin Microbiol Infect. 24(5):476–482.
   PubMed Web of Science ®Google Scholar
• Choi MS, Yu JS, Yoo HH, Kim DH. 2018. The role of gut microbiota in the pharmacokinetics of antihypertensive drugs. Pharmacol Res. 130:164–171.
   PubMed Web of Science ®Google Scholar
• Chu F, Li Y, Meng X, Li Y, Li T, Zhai M, Zheng H, Xin T, Su Z, Lin J, et al. 2021. Gut microbial dysbiosis and changes in fecal metabolic phenotype in precancerous lesions of gastric cancer induced with N-methyl-N'-nitro-N-nitrosoguanidine, sodium salicylate, ranitidine, and irregular diet. Front Physiol. 12:733979.
   PubMed Web of Science ®Google Scholar
• Cussotto S, Walsh J, Golubeva AV, Zhdanov AV, Strain CR, Fouhy F, Stanton C, Dinan TG, Hyland NP, Clarke G, et al. 2021. The gut microbiome influences the bioavailability of olanzapine in rats. EBioMedicine. 66:103307.
   PubMed Web of Science ®Google Scholar
• Dobkin JF, Saha JR, Butler VP, Jr., Neu HC, Lindenbaum J. 1982. Inactivation of digoxin by Eubacterium lentum, an anaerobe of the human gut flora. Trans Assoc Am Physicians. 95:22–29.
   PubMedGoogle Scholar
• Dull BJ, Salata K, Goldman P. 1987. Role of the intestinal flora in the acetylation of sulfasalazine metabolites. Biochem Pharmacol. 36(21):3772–3774.
   PubMed Web of Science ®Google Scholar
• Fan J, de Lannoy IA. 2014. Pharmacokinetics. Biochem Pharmacol. 87(1):93–120.
   PubMed Web of Science ®Google Scholar
• Finegold SM. 1986. Anaerobic infections and Clostridium difficile colitis emerging during antibacterial therapy. Scand J Infect Dis Suppl. 49:160–164.
   PubMedGoogle Scholar
• Fouts JR, Kamm JJ, Brodie BB. 1957. Enzymatic reduction of prontosil and other azo dyes. J Pharmacol Exp Ther. 120(3):291–300.
   PubMed Web of Science ®Google Scholar
• Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, Schrenk D. 2000. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol. 157(5):1575–1580.
   PubMed Web of Science ®Google Scholar
• Genser D. 2008. Food and drug interaction: consequences for the nutrition/health status. Ann Nutr Metab. 52(Suppl 1):29–32.
   PubMed Web of Science ®Google Scholar
• Gezmen-Karadağ M, Çelik E, Kadayifçi FZ, Yeşildemir Ö, Öztürk YE, Ağagündüz D. 2018. Role of food‑drug interactions in neurological and psychological diseases. Acta Neurobiol Exp. 78(3):187–197.
   PubMed Web of Science ®Google Scholar
• Gingell R, Bridges JW. 1973. Intestinal azo-reduction and glucuronide conjugation of prontosil. Xenobiotica. 3(9):599–604.
   PubMed Web of Science ®Google Scholar
• Gingell R, Bridges JW, Williams RT. 1971. The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat. Xenobiotica. 1(2):143–156.
   PubMedGoogle Scholar
• Goldin BR, Peppercorn MA, Goldman P. 1973. Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. J Pharmacol Exp Ther. 186(1):160–166.
   PubMed Web of Science ®Google Scholar
• Goldman P, Peppercorn MA, Goldin BR. 1974. Metabolism of drugs by microorganisms in the intestine. Am J Clin Nutr. 27(11):1348–1355.
   PubMed Web of Science ®Google Scholar
• Gomaa EZ. 2020. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 113(12):2019–2040.
   PubMed Web of Science ®Google Scholar
• Greenhalgh K, Meyer KM, Aagaard KM, Wilmes P. 2016. The human gut microbiome in health: establishment and resilience of microbiota over a lifetime. Environ Microbiol. 18(7):2103–2116.
   PubMed Web of Science ®Google Scholar
• Grenham S, Clarke G, Cryan JF, Dinan TG. 2011. Brain-gut-microbe communication in health and disease. Front Physiol. 2:94.
   PubMed Web of Science ®Google Scholar
• Guinane CM, Cotter PD. 2013. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol. 6(4):295–308.
   PubMed Web of Science ®Google Scholar
• Gunzburg WH, Aung MM, Toa P, Ng S, Read E, Tan WJ, Brandtner EM, Dangerfield J, Salmons B. 2020. Efficient protection of microorganisms for delivery to the intestinal tract by cellulose sulphate encapsulation. Microb Cell Fact. 19(1):216.
   PubMed Web of Science ®Google Scholar
• Guthrie L, Kelly L. 2019. Bringing microbiome-drug interaction research into the clinic. EBioMedicine. 44:708–715.
   PubMed Web of Science ®Google Scholar
• Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. 2013. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science. 341(6143):295–298.
   PubMed Web of Science ®Google Scholar
• Harris BE, Manning BW, Federle TW, Diasio RB. 1986. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother. 29(1):44–48.
   PubMed Web of Science ®Google Scholar
• Hasan N, Yang H. 2019. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ. 7:e7502.
   PubMed Web of Science ®Google Scholar
• Hattori M, Sakamoto T, Kobashi K, Namba T. 1983. Metabolism of glycyrrhizin by human intestinal flora. Planta Med. 48(1):38–42.
   PubMed Web of Science ®Google Scholar
• Hayllar J, Bjarnason I. 1991. Sulphasalazine in ulcerative colitis: in memoriam? Gut. 32(5):462–463.
   PubMed Web of Science ®Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. 1998. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev. 50(3):387–412.
   PubMed Web of Science ®Google Scholar
• Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. 2015. Role of the normal gut microbiota. World J Gastroenterol. 21(29):8787–8803.
   PubMed Web of Science ®Google Scholar
• Jang HM, Lee HJ, Jang SE, Han MJ, Kim DH. 2018. Evidence for interplay among antibacterial-induced gut microbiota disturbance, neuro-inflammation, and anxiety in mice. Mucosal Immunol. 11(5):1386–1397.
   PubMed Web of Science ®Google Scholar
• Javdan B, Lopez JG, Chankhamjon P, Lee YJ, Hull R, Wu Q, Wang X, Chatterjee S, Donia MS. 2020. Personalized mapping of drug metabolism by the human gut microbiome. Cell. 181(7):1661–1679.e1622.
   PubMed Web of Science ®Google Scholar
• Kamali F, Huang ML. 1996. Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. Br J Clin Pharmacol. 41(2):125–128.
   PubMed Web of Science ®Google Scholar
• Kantola T, Kivistö KT, Neuvonen PJ. 1998. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 64(2):177–182.
   PubMed Web of Science ®Google Scholar
• Kehrer DF, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, Ruijgrok EJ, de Jonge MJ. 2001. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res. 7(5):1136–1141.
   PubMed Web of Science ®Google Scholar
• Kim DH. 2015. Gut microbiota-mediated drug-antibiotic interactions. Drug Metab Dispos. 43(10):1581–1589.
   PubMed Web of Science ®Google Scholar
• Kim DH, Hong SW, Kim BT, Bae EA, Park HY, Han MJ. 2000. Biotransformation of glycyrrhizin by human intestinal bacteria and its relation to biological activities. Arch Pharm Res. 23(2):172–177.
   PubMed Web of Science ®Google Scholar
• Kim DH, Hyun SH, Shim SB, Kobashi K. 1992. The role of intestinal bacteria in the transformation of sodium picosulfate. Jpn J Pharmacol. 59(1):1–5.
   PubMedGoogle Scholar
• Kim DH, Kobashi K. 1986. The role of intestinal flora in metabolism of phenolic sulfate esters. Biochem Pharmacol. 35(20):3507–3510.
   PubMed Web of Science ®Google Scholar
• Kim DH, Yoon HK, Koizumi M, Kobashi K. 1992. Sulfation of phenolic antibiotics by sulfotransferase obtained from a human intestinal bacterium. Chem Pharm Bull. 40(4):1056–1057.
   PubMed Web of Science ®Google Scholar
• Kim IS, Yoo DH, Jung IH, Lim S, Jeong JJ, Kim KA, Bae ON, Yoo HH, Kim DH. 2016. Reduced metabolic activity of gut microbiota by antibiotics can potentiate the antithrombotic effect of aspirin. Biochem Pharmacol. 122:72–79.
   PubMed Web of Science ®Google Scholar
• Kim JK, Choi MS, Jeong JJ, Lim SM, Kim IS, Yoo HH, Kim DH. 2018. Effect of probiotics on pharmacokinetics of orally administered acetaminophen in mice. Drug Metab Dispos. 46(2):122–130.
   PubMed Web of Science ®Google Scholar
• Kim JK, Choi MS, Kim JY, Yu JS, Seo JI, Yoo HH, Kim DH. 2021. Ginkgo biloba leaf extract suppresses intestinal human breast cancer resistance protein expression in mice: correlation with gut microbiota. Biomed Pharmacother. 140:111712.
   PubMed Web of Science ®Google Scholar
• Kim JK, Choi MS, Yoo HH, Kim DH. 2022. The intake of coffee increases the absorption of aspirin in mice by modifying gut microbiome. Pharmaceutics. 14(4):746.
   PubMed Web of Science ®Google Scholar
• Kim JK, Han SK, Joo MK, Kim DH. 2021. Buspirone alleviates anxiety, depression, and colitis; and modulates gut microbiota in mice. Sci Rep. 11(1):6094.
   PubMed Web of Science ®Google Scholar
• Kitamura S, Sugihara K, Kuwasako M, Tatsumi K. 1997. The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol. 49(3):253–256.
   PubMed Web of Science ®Google Scholar
• Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ. 1997. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther. 62(3):348–354.
   PubMed Web of Science ®Google Scholar
• Klotz U. 1985. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet. 10(4):285–302.
   PubMed Web of Science ®Google Scholar
• Koch RL, Beaulieu BB, Jr., Goldman P. 1980. Role of the intestinal flora in the metabolism of misonidazole. Biochem Pharmacol. 29(24):3281–3284.
   PubMed Web of Science ®Google Scholar
• Koch RL, Goldman P. 1979. The anaerobic metabolism of metronidazole forms N-(2-hydroxyethyl)-oxamic acid. J Pharmacol Exp Ther. 208(3):406–410.
   PubMed Web of Science ®Google Scholar
• Kock RL, Beaulieu BB, Jr., Chrystal EJ, Goldman P. 1981. A metronidazole metabolite in human urine and its risk. Science. 211(4480):398–400.
   PubMed Web of Science ®Google Scholar
• Konop M, Radkowski M, Grochowska M, Perlejewski K, Samborowska E, Ufnal M. 2018. Enalapril decreases rat plasma concentration of TMAO, a gut bacteria-derived cardiovascular marker. Biomarkers. 23(4):380–385.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Alden N, Lee K. 2015. Pathways and functions of gut microbiota metabolism impacting host physiology. Curr Opin Biotechnol. 36:137–145.
   PubMed Web of Science ®Google Scholar
• Lai Y, Chu X, Di L, Gao W, Guo Y, Liu X, Lu C, Mao J, Shen H, Tang H, et al. 2022. Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. Acta Pharm Sin B. 12(6):2751–2777.
   PubMed Web of Science ®Google Scholar
• Lange K, Buerger M, Stallmach A, Bruns T. 2016. Effects of antibiotics on gut microbiota. Dig Dis. 34(3):260–268.
   PubMed Web of Science ®Google Scholar
• Lavrijsen K, van Dyck D, van Houdt J, Hendrickx J, Monbaliu J, Woestenborghs R, Meuldermans W, Heykants J. 1995. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans. Drug Metab Dispos. 23(3):354–362.
   PubMed Web of Science ®Google Scholar
• Leclercq S, Mian FM, Stanisz AM, Bindels LB, Cambier E, Ben-Amram H, Koren O, Forsythe P, Bienenstock J. 2017. Low-dose penicillin in early life induces long-term changes in murine gut microbiota, brain cytokines and behavior. Nat Commun. 8(1):15062.
   PubMedGoogle Scholar
• Lee CB, Chae SU, Jo SJ, Jerng UM, Bae SK. 2021. The relationship between the gut microbiome and metformin as a key for treating type 2 diabetes mellitus. Int J Mol Sci. 22(7):3566.
   PubMed Web of Science ®Google Scholar
• Lee KE, Kim JK, Kim DH. 2020. Orally administered antibiotics vancomycin and ampicillin cause cognitive impairment with gut dysbiosis in mice with transient global forebrain ischemia. Front Microbiol. 11:564271.
   PubMed Web of Science ®Google Scholar
• Lee SC, Renwick AG. 1995. Sulphoxide reduction by rat intestinal flora and by Escherichia coli in vitro. Biochem Pharmacol. 49(11):1567–1576.
   PubMed Web of Science ®Google Scholar
• Lee SH, An JH, Lee HJ, Jung BH. 2012. Evaluation of pharmacokinetic differences of acetaminophen in pseudo germ-free rats. Biopharm Drug Dispos. 33(6):292–303.
   PubMed Web of Science ®Google Scholar
• Lepage P, Leclerc MC, Joossens M, Mondot S, Blottière HM, Raes J, Ehrlich D, Doré J. 2013. A metagenomic insight into our gut’s microbiome. Gut. 62(1):146–158.
   PubMed Web of Science ®Google Scholar
• Levy G. 1981. Comparative pharmacokinetics of aspirin and acetaminophen. Arch Intern Med. 141(3 Spec No):279–281.
   PubMedGoogle Scholar
• Li F, Liu B, Li T, Wu Q, Xu Z, Gu Y, Li W, Wang P, Ma T, Lei H. 2020. Review of constituents and biological activities of triterpene Saponins from Glycyrrhizae Radix et Rhizoma and its solubilization characteristics. Molecules. 25(17):3904.
   PubMed Web of Science ®Google Scholar
• Li W, Tan F, Zhao K. 2006. Simultaneous determination of amoxicillin and ranitidine in rat plasma by high-performance liquid chromatography. J Pharm Biomed Anal. 41(2):594–598.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao D, Qian M, Liu J, Pan C, Zhang X, Duan X, Zhang Y, Jia W, Wang L. 2022. Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. Br J Pharmacol. 179(9):2054–2077.
   PubMed Web of Science ®Google Scholar
• Lindenbaum J, Maulitz RM, Butler VP. Jr. 1976. Inhibition of digoxin absorption by neomycin. Gastroenterology. 71(3):399–404.
   PubMed Web of Science ®Google Scholar
• Lindenbaum J, Rund DG, Butler VP, Jr., Tse-Eng D, Saha JR. 1981. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med. 305(14):789–794.
   PubMed Web of Science ®Google Scholar
• Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. 2012. Diversity, stability and resilience of the human gut microbiota. Nature. 489(7415):220–230.
   PubMed Web of Science ®Google Scholar
• Lu H. 2007. Stereoselectivity in drug metabolism. Expert Opin Drug Metab Toxicol. 3(2):149–158.
   PubMed Web of Science ®Google Scholar
• Ma X, Shin YJ, Jang HM, Joo MK, Yoo JW, Kim DH. 2021. Lactobacillus Rhamnosus and Bifidobacterium Longum alleviate colitis and cognitive impairment in mice by regulating IFN-γ to IL-10 and TNF-α to IL-10 expression ratios. Sci Rep. 11(1):20659.
   PubMed Web of Science ®Google Scholar
• Machavaram KK, Gundu J, Yamsani MR. 2006. Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein. Drug Metabol Drug Interact. 22(1):47–65.
   PubMedGoogle Scholar
• Mahatthanatrakul W, Nontaput T, Ridtitid W, Wongnawa M, Sunbhanich M. 2007. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. J Clin Pharm Ther. 32(2):161–167.
   PubMed Web of Science ®Google Scholar
• Malet-Martino MC, Martino R, de Forni M, Andremont A, Hartmann O, Armand JP. 1991. Flucytosine conversion to fluorouracil in humans: does a correlation with gut flora status exist? A report of two cases using fluorine-19 magnetic resonance spectroscopy. Infection. 19(3):178–180.
   PubMed Web of Science ®Google Scholar
• Matuskova Z, Anzenbacher P, Vecera R, Siller M, Tlaskalova-Hogenova H, Strojil J, Anzenbacherova E. 2017. Effect of lactobacillus casei on the pharmacokinetics of amiodarone in male wistar rats. Eur J Drug Metab Pharmacokinet. 42(1):29–36.
   PubMed Web of Science ®Google Scholar
• Matuskova Z, Anzenbacherova E, Vecera R, Tlaskalova-Hogenova H, Kolar M, Anzenbacher P. 2014. Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats. PLOS One. 9(2):e87150.
   PubMed Web of Science ®Google Scholar
• Methaneethorn J, Chaiwong K, Pongpanich K, Sonsingh P, Lohitnavy M. 2014. A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans. Annu Int Conf IEEE Eng Med Biol Soc. 2014:5703–5706.
   PubMedGoogle Scholar
• Meuldermans W, Hendrickx J, Mannens G, Lavrijsen K, Janssen C, Bracke J, Le Jeune L, Lauwers W, Heykants J. 1994. The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos. 22(1):129–138.
   PubMed Web of Science ®Google Scholar
• Müller M, Hermes GDA, Canfora EE, Smidt H, Masclee AAM, Zoetendal EG, Blaak EE. 2020. Distal colonic transit is linked to gut microbiota diversity and microbial fermentation in humans with slow colonic transit. Am J Physiol Gastrointest Liver Physiol. 318(2):G361–g369.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Tamai I. 2015. Interaction of drug or food with drug transporters in intestine and liver. Curr Drug Metab. 16(9):753–764.
   PubMed Web of Science ®Google Scholar
• Ochs HR, Greenblatt DJ, Eichelkraut W, LeDuc BW, Powers JF, Hahn N. 1991. Contribution of the gastrointestinal tract to lorazepam conjugation and clonazepam nitroreduction. Pharmacology. 42(1):36–48.
   PubMed Web of Science ®Google Scholar
• Pant A, Maiti TK, Mahajan D, Das B. 2022. Human gut microbiota and drug metabolism. Microb Ecol. 1, 1–15.
   Google Scholar
• Parvez MM, Basit A, Jariwala PB, Gáborik Z, Kis E, Heyward S, Redinbo MR, Prasad B. 2021. Quantitative investigation of irinotecan metabolism, transport, and gut microbiome activation. Drug Metab Dispos. 49(8):683–693.
   PubMed Web of Science ®Google Scholar
• Peppercorn MA, Goldman P. 1973. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology. 64(2):240–245.
   PubMed Web of Science ®Google Scholar
• Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. 2019. Mechanisms of action of probiotics. Adv Nutr. 10(suppl_1): s49–s66.
   PubMed Web of Science ®Google Scholar
• Purohit SD, Johri SC, Gupta PR, Mehta YR, Bhatnagar M. 1992. Ranitidine–rifampicin interaction. J Assoc Physicians India. 40(5):308–310.
   PubMedGoogle Scholar
• Qian G, Ho JWK. 2020. Challenges and emerging systems biology approaches to discover how the human gut microbiome impact host physiology. Biophys Rev. 12(4):851–863.
   PubMedGoogle Scholar
• Rafii F, Sutherland JB, Hansen EB, Jr., Cerniglia CE. 1997. Reduction of nitrazepam by Clostridium leptum, a nitroreductase-producing bacterium isolated from the human intestinal tract. Clin Infect Dis. 25(Suppl 2):S121–S122.
   PubMedGoogle Scholar
• Ratnaike RN, Jones TE. 1998. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging. 13(3):245–253.
   PubMed Web of Science ®Google Scholar
• Ravindran S, Suthar JK, Rokade R, Deshpande P, Singh P, Pratinidhi A, Khambadkhar R, Utekar S. 2018. Pharmacokinetics, metabolism, distribution and permeability of nanomedicine. Curr Drug Metab. 19(4):327–334.
   PubMed Web of Science ®Google Scholar
• Ren Y, Nie L, Zhu S, Zhang X. 2022. Nanovesicles-mediated drug delivery for oral bioavailability enhancement. Int J Nanomedicine. 17:4861–4877.
   PubMed Web of Science ®Google Scholar
• Ridlon JM, Ikegawa S, Alves JM, Zhou B, Kobayashi A, Iida T, Mitamura K, Tanabe G, Serrano M, De Guzman A, et al. 2013. Clostridium Scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens. J Lipid Res. 54(9):2437–2449.
   PubMed Web of Science ®Google Scholar
• Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, Mele MC. 2019. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 7(1):14.
   PubMed Web of Science ®Google Scholar
• Rodin SM, Johnson BF. 1988. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet. 15(4):227–244.
   PubMed Web of Science ®Google Scholar
• Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, Tuohy K. 2018. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 57(1):1–24.
   PubMed Web of Science ®Google Scholar
• Saha JR, Butler VP, Jr., Neu HC, Lindenbaum J. 1983. Digoxin-inactivating bacteria: identification in human gut flora. Science. 220(4594):325–327.
   PubMed Web of Science ®Google Scholar
• Saksena S, Goyal S, Raheja G, Singh V, Akhtar M, Nazir TM, Alrefai WA, Gill RK, Dudeja PK. 2011. Upregulation of P-glycoprotein by probiotics in intestinal epithelial cells and in the dextran sulfate sodium model of colitis in mice. Am J Physiol Gastrointest Liver Physiol. 300(6):G1115–G1123.
   PubMed Web of Science ®Google Scholar
• Sandler M, Karoum F, Ruthven CR, Calne DB. 1969. m-Hydroxyphenylacetic acid formation from L-dopa in man: suppression by neomycin. Science. 166(3911):1417–1418.
   PubMed Web of Science ®Google Scholar
• Saputri FA, Kang D, Kusuma ASW, Rusdiana T, Hasanah AN, Surono IS, Koyama H, Abdulah, R, Mutakin  . 2018. Lactobacillus Plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. J Int Med Res. 46(12):5004–5010.
   PubMed Web of Science ®Google Scholar
• Scherrmann JM. 2009. Transporters in absorption, distribution, and elimination. Chem Biodivers. 6(11):1933–1942.
   PubMed Web of Science ®Google Scholar
• Schmidt LE, Dalhoff K. 2002. Food-drug interactions. Drugs. 62(10):1481–1502.
   PubMed Web of Science ®Google Scholar
• Scorza C, Piccini C, Martínez Busi M, Abin Carriquiry JA, Zunino P. 2019. Alterations in the gut microbiota of rats chronically exposed to volatilized cocaine and its active adulterants caffeine and phenacetin. Neurotox Res. 35(1):111–121.
   PubMed Web of Science ®Google Scholar
• Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW. 2014. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 63(5):727–735.
   PubMed Web of Science ®Google Scholar
• Shu YZ, Kingston DG, Van Tassell RL, Wilkins TD. 1991. Metabolism of levamisole, an anti-colon cancer drug, by human intestinal bacteria. Xenobiotica. 21(6):737–750.
   PubMed Web of Science ®Google Scholar
• Smith GE, Griffiths LA. 1974. Metabolism of N-acylated and O-alkylated drugs by the intestinal microflora during anaerobic incubation in vitro. Xenobiotica. 4(8):477–487.
   PubMed Web of Science ®Google Scholar
• Smith TW. 1985. Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. J Am Coll Cardiol. 5(5):43A–50A.
   PubMed Web of Science ®Google Scholar
• Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. 2008. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm. 363(1–2):1–25.
   PubMed Web of Science ®Google Scholar
• Stojančević M, Bojić G, Salami HA, Mikov M. 2014. The influence of intestinal tract and probiotics on the fate of orally administered drugs. Curr Issues Mol Biol. 16:55–68.
   PubMed Web of Science ®Google Scholar
• Strong HA, Renwick AG, George CF. 1984. The site of reduction of sulphinpyrazone in the rabbit. Xenobiotica. 14(10):815–826.
   PubMed Web of Science ®Google Scholar
• Strong HA, Renwick AG, George CF, Liu YF, Hill MJ. 1987. The reduction of sulphinpyrazone and sulindac by intestinal bacteria. Xenobiotica. 17(6):685–696.
   PubMed Web of Science ®Google Scholar
• Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. 2000. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev. 1998(2):Cd000958.
   PubMedGoogle Scholar
• Takeno S, Hirano Y, Kitamura A, Sakai T. 1993. Comparative developmental toxicity and metabolism of nitrazepam in rats and mice. Toxicol Appl Pharmacol. 121(2):233–238.
   PubMed Web of Science ®Google Scholar
• Takeno S, Nakagawa M, Sakai T. 1990. Teratogenic effects of nitrazepam in rats. Res Commun Chem Pathol Pharmacol. 69(1):59–70.
   PubMedGoogle Scholar
• Testa B, Krämer SD. 2009. The biochemistry of drug metabolism–an introduction: part 5. Metabolism and bioactivity. C&B. 6(5):591–684.
   Google Scholar
• Tisdale WA, Fenster LF, Klatskin G. 1960. Acute staphylococcal enterocolitis complicating oral neomycin therapy in cirrhosis. N Engl J Med. 263:1014–1016.
   PubMed Web of Science ®Google Scholar
• Umu ÖC, Rudi K, Diep DB. 2017. Modulation of the gut microbiota by prebiotic fibres and bacteriocins. Microb Ecol Health Dis. 28(1):1348886.
   PubMedGoogle Scholar
• van Berlo CL, van Leeuwen PA, Soeters PB. 1988. Porcine intestinal ammonia liberation. Influence of food intake, lactulose and neomycin treatment. J Hepatol. 7(2):250–257.
   PubMed Web of Science ®Google Scholar
• van de Steeg E, Schuren FHJ, Obach RS, van Woudenbergh C, Walker GS, Heerikhuisen M, Nooijen IHG, Vaes WHJ. 2018. An ex vivo fermentation screening platform to study drug metabolism by human gut microbiota. Drug Metab Dispos. 46(11):1596–1607.
   PubMed Web of Science ®Google Scholar
• Vermes A, Kuijper EJ, Guchelaar HJ, Dankert J. 2003. An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora. Chemotherapy. 49(1–2):17–23.
   PubMed Web of Science ®Google Scholar
• Weersma RK, Zhernakova A, Fu J. 2020. Interaction between drugs and the gut microbiome. Gut. 69(8):1510–1519.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Kurita A, Asahara T, Takakura A, Katono K, Iwasaki M, Ryuge S, Wada M, Onoda S, Yanaihara T. 2008. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol Rep. 20(4):727–730.
   PubMed Web of Science ®Google Scholar
• Yang T, Mei X, Tackie-Yarboi E, Akere MT, Kyoung J, Mell B, Yeo JY, Cheng X, Zubcevic J, Richards EM, et al. 2022. Identification of a gut commensal that compromises the blood pressure-lowering effect of ester angiotensin-converting enzyme inhibitors. Hypertension. 79(8):1591–1601.
   PubMed Web of Science ®Google Scholar
• Yendapally R, Sikazwe D, Kim SS, Ramsinghani S, Fraser-Spears R, Witte AP, La-Viola B. 2020. A review of phenformin, metformin, and imeglimin. Drug Dev Res. 81(4):390–401.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Kim IS, Van Le TK, Jung IH, Yoo HH, Kim DH. 2014. Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab Dispos. 42(9):1508–1513.
   PubMed Web of Science ®Google Scholar
• Yoo HH, Kim IS, Yoo D-H, Kim D-H. 2016. Effects of orally administered antibiotics on the bioavailability of amlodipine: gut microbiota-mediated drug interaction. J Hypertens. 34(1):156–162.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen Y, Sun Y, Wang R, Zhang J, Jia Z. 2018. Plateau hypoxia attenuates the metabolic activity of intestinal flora to enhance the bioavailability of nifedipine. Drug Deliv. 25(1):1175–1181.
   PubMed Web of Science ®Google Scholar
• Zhang X, Han Y, Huang W, Jin M, Gao Z. 2021. The influence of the gut microbiota on the bioavailability of oral drugs. Acta Pharm Sin B. 11(7):1789–1812.
   PubMed Web of Science ®Google Scholar
• Zhao TS, Xie LW, Cai S, Xu JY, Zhou H, Tang LF, Yang C, Fang S, Li M, Tian Y. 2021. Dysbiosis of gut microbiota is associated with the progression of radiation-induced intestinal injury and is alleviated by oral compound probiotics in mouse model. Front Cell Infect Microbiol. 11:717636.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. 2019a. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 570(7762):462–467.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. 2019b. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science. 363(6427):aat9931.
   Web of Science ®Google Scholar